Shares of Aurinia Pharmaceuticals (NASDAQ: NASDAQ:AUPH) saw a notable increase today, rising by 6.7% amid speculation about a potential acquisition by Gilead Sciences (NASDAQ:GILD). The...
Kite, a Gilead Company (GILD), and Arcellx, Inc. (ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.Kite...
An analyst from RBC Capital maintained Gilead (NASDAQ: GILD) at 'sector perform' with a price target of $77.00 from a prior price target of %currency%%price%. Prior to this rating, Gilead...
Investing.com -- The Dow closed lower Thursday, as Federal Reserve chairman Jerome Powell dealt a blow to bets on sooner rather later rate cuts after signaling that the Fed isn't ready to...
An analyst from Deutsche Bank initiated coverage of Gilead (NASDAQ: GILD) at 'hold' with a price target of $75.00. Prior to this rating, Gilead had 17 buy ratings, 12 hold ratings, and 1...
Investing.com -- U.S. stocks were wobbling on Wednesday amid a slew of earnings reports, as investors await a second public appearance this week by Federal Reserve Chair Jerome Powell, who...
An analyst from Jefferies maintained Gilead (NASDAQ: GILD) at 'buy' with a price target of $95.00 from a prior price target of %currency%%price%. Prior to this rating, Gilead had 17 buy...
An analyst from Barclays maintained Gilead (NASDAQ: GILD) at 'equalweight' with a price target of $82.00 from a prior price target of %currency%%price%. Prior to this rating, Gilead had 17...
After-Hours Stock Movers:Upstart Holdings (NASDAQ:UPST) 20% LOWER; reported Q3 EPS of ($0.05), $0.03 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $135...
Investing.com - Gilead (NASDAQ: GILD) reported third quarter EPS of $2.29, $0.38 better than the analyst estimate of $1.91. Revenue for the quarter came in at $7.1B versus the consensus...
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR)...
An analyst from UBS maintained Gilead (NASDAQ: GILD) at 'neutral' with a price target of $85.00 from a prior price target of %currency%%price%. Prior to this rating, Gilead had 17 buy...
Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic...
Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca® (lenacapavir) as an important treatment option for adults with multi-drug resistant (MDR) HIV who have...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will...
Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) and Assembly Biosciences, Inc. (Nasdaq: NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
New York, USA, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Epstein-Barr Virus Market Likely to Exhibit Substantial Growth by 2032, Examines DelveInsight | Key Players in the Market - Viracta,...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in combination...
BofA analysts upgraded shares of Gilead Sciences (NASDAQ:GILD) to Buy from Neutral, with a price target of $95, up from $88 per share, in a note to clients on Friday. The analysts told...
(Updated - September 8, 2023 6:40 AM EDT) BofA Securities analyst upgraded Gilead Sciences (NASDAQ:GILD) from Neutral to Buy with a price target of $95.00 (from $88.00).The analyst...
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior...
HSBC initiated coverage of 11 U.S. biopharmaceutical and healthcare stocks in a note to clients on Wednesday. Analysts assigned Actinium Pharmaceuticals Inc (NYSE:ATNM), Amgen (NASDAQ:AMGN),...
An analyst from HSBC initiated coverage of Gilead (NASDAQ: GILD) at 'reduce' with a price target of $71.00. Prior to this rating, Gilead had 13 buy ratings, 14 hold ratings, and 1 sell...
MacroGenics, Inc. (NASDAQ:MGNX) today announced that its partner, Gilead Sciences, Inc. (NASDAQ:GILD), nominated the first of two research programs, leveraging MacroGenics’ DART® and...
Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury®...
Gilead Sciences (NASDAQ:GILD) announced Monday that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on the initiation of new patients in U.S. studies...
Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S....
Truist Securities analyst reiterated a Buy rating and $91.00 price target on Gilead Sciences (NASDAQ:GILD) after, at WCLC, leaked EVOKE-2 preliminary data displayed an encouraging profile in...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
